Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 1/2016

01-01-2016 | Editorial

Periostin on the road to nonalcoholic fatty liver disease

Authors: Stergios A. Polyzos, Athanasios D. Anastasilakis

Published in: Endocrine | Issue 1/2016

Login to get access

Excerpt

Nonalcoholic fatty liver disease (NAFLD) is a global public health issue, affecting approximately one-third of the general population. NAFLD ranges from nonalcoholic simple steatosis (SS) to nonalcoholic steatohepatitis (NASH), characterized by inflammation and/or fibrosis, NASH-related cirrhosis and hepatocellular carcinoma [1]. Liver biopsy remains the gold standard in the diagnosis of NAFLD, although identification of noninvasive biomarkers is a field of intense research [2]. Even more, despite its high prevalence, the treatment of NAFLD currently remains an unmet medical need [3]. …
Literature
1.
S.A. Polyzos, J. Kountouras, C. Zavos, Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines. Curr. Mol. Med. 9, 299–314 (2009)PubMedCrossRef
2.
S.A. Polyzos, C.S. Mantzoros, Necessity for timely noninvasive diagnosis of nonalcoholic fatty liver disease. Metabolism 63, 161–167 (2014)PubMedCrossRef
3.
S.A. Polyzos, J. Kountouras, C. Zavos, G. Deretzi, Nonalcoholic fatty liver disease: multimodal treatment options for a pathogenetically multiple-hit disease. J. Clin. Gastroenterol. 46, 272–284 (2012)PubMedCrossRef
4.
A.Y. Liu, H. Zheng, G. Ouyang, Periostin, a multifunctional matricellular protein in inflammatory and tumor microenvironments. Matrix Biol. 37, 150–156 (2014)PubMedCrossRef
5.
J.C. Rousseau, E. Sornay-Rendu, C. Bertholon, R. Chapurlat, P. Garnero, Serum periostin is associated with fracture risk in postmenopausal women: a 7-year prospective analysis of the OFELY study. J. Clin. Endocrinol. Metab. 99, 2533–2539 (2014)PubMedCrossRef
6.
A.D. Anastasilakis, S.A. Polyzos, P. Makras, M. Savvides, G.T. Sakellariou, A. Gkiomisi, A. Papatheodorou, E. Terpos, Circulating periostin levels do not differ between postmenopausal women with normal and low bone mass and are not affected by zoledronic acid treatment. Horm. Metab. Res. 46, 145–149 (2014)PubMed
7.
Y. Lu, X. Liu, Y. Jiao, X. Xiong, E. Wang, X. Wang, Z. Zhang, H. Zhang, L. Pan, Y. Guan, D. Cai, G. Ning, X. Li, Periostin promotes liver steatosis and hypertriglyceridemia through downregulation of PPARα. J. Clin. Invest. 124, 3501–3513 (2014)PubMedPubMedCentralCrossRef
8.
Y. Li, S. Wu, S. Xiong, G. Ouyang, Deficiency of periostin protects mice against methionine-choline-deficient diet-induced non-alcoholic steatohepatitis. J. Hepatol. 62, 495–497 (2015)PubMedCrossRef
9.
Y. Huang, W. Liu, H. Xiao, A. Maitikabili, Q. Lin, T. Wu, Z. Huang, F. Liu, Q. Luo, G. Ouyang, Matricellular protein periostin contributes to hepatic inflammation and fibrosis. Am. J. Pathol. 185, 786–797 (2015)PubMedCrossRef
10.
S. Amara, K. Lopez, B. Banan, S.K. Brown, M. Whalen, E. Myles, M.T. Ivy, T. Johnson, K.L. Schey, V. Tiriveedhi, Synergistic effect of pro-inflammatory TNFα and IL-17 in periostin mediated collagen deposition: potential role in liver fibrosis. Mol. Immunol. 64, 26–35 (2015)PubMedCrossRef
11.
J.Z. Zhu, H.T. Zhu, Y.N. Dai, C.X. Li, Z.Y. Fang, D.J. Zhao, X.Y. Wan, Y.M. Wang, F. Wang, C.H. Yu, Y.M. Li, Serum periostin is a potential biomarker for non-alcoholic fatty liver disease: a case-control study. Endocrine (2015). doi:10.​1007/​s12020-015-0735-2
12.
Y. Lv, W. Wang, W.D. Jia, Q.K. Sun, M. Huang, H.C. Zhou, H.H. Xia, W.B. Liu, H. Chen, S.N. Sun, G.L. Xu, High preoperative levels of serum periostin are associated with poor prognosis in patients with hepatocellular carcinoma after hepatectomy. Eur. J. Surg. Oncol. 39, 1129–1135 (2013)PubMedCrossRef
13.
Y.J. Lee, I.S. Kim, S.A. Park, Y. Kim, J.E. Lee, D.Y. Noh, K.T. Kim, S.H. Ryu, P.G. Suh, Periostin-binding DNA aptamer inhibits breast cancer growth and metastasis. Mol. Ther. 21, 1004–1013 (2013)PubMedPubMedCentralCrossRef
14.
G.X. Liu, H.Q. Xi, X.Y. Sun, B. Wei, Role of periostin and its antagonist PNDA-3 in gastric cancer metastasis. World J. Gastroenterol. 21, 2605–2613 (2015)PubMedPubMedCentralCrossRef
Metadata
Title
Periostin on the road to nonalcoholic fatty liver disease
Authors
Stergios A. Polyzos
Athanasios D. Anastasilakis
Publication date
01-01-2016
Publisher
Springer US
Published in
Endocrine / Issue 1/2016
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-015-0803-7

Other articles of this Issue 1/2016

Endocrine 1/2016 Go to the issue

Editorial

Preoperative staging in childhood craniopharyngioma: standardization as a first step towards improved outcome

Review

Sheehan’s syndrome: new insights into an old disease

Original Article

Testosterone stimulates glucose uptake and GLUT4 translocation through LKB1/AMPK signaling in 3T3-L1 adipocytes

Original Article

Minimally invasive follicular carcinoma: predictors of vascular invasion and impact on patterns of care

Original Article

Clinical management of patients with gastric neuroendocrine neoplasms associated with chronic atrophic gastritis: a retrospective, multicentre study

View Point

Tackling inadequate vitamin D intakes within the population: fortification of dairy products with vitamin D may not be enough
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits